Connect Biopharma Holdings Ltd ADR (CNTB) Stock Price, Quote & News

Company Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquarte...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 727 1040

Website: www.connectbiopharm.com

Address:

3580 CARMEL MOUNTAIN ROAD, SUITE 200, San Diego, United States

RunnerSignals Dec. 2 at 8:20 PM

$BLTE $CDRE $CEVA $CHYM $CNTB Some serious fireworks here also! https://stocksrunner.com/news/2025-12-02-stock-upgrades-today-highlight-top-picks

0 · Reply

mikeywo Dec. 2 at 5:33 PM

$CNTB lackluster fireside chat ?

0 · Reply

DARKP00L Dec. 1 at 5:18 PM

$CNTB 12:01 on Dec. 01 2025 Lake Street Initiates Coverage On Connect Biopharma Hldgs with Buy Rating, Announces Price Target of $9 #tradeideas

0 · Reply

JarvisFlow Dec. 1 at 5:01 PM

Lake Street has updated their rating for Connect Biopharma Hldgs ( $CNTB ) to Buy with a price target of 9.

0 · Reply

LabPsycho Nov. 26 at 7:28 PM

$CNTB @mikeywo But can you trust the data?

2 · Reply

Schlombo Nov. 24 at 9:28 PM

$CNTB any thoughts on the 2 million shares picked up at close? Smart money? Maybe a rebalancing?

0 · Reply

mikeywo Nov. 21 at 12:42 PM

$CNTB picked up 16 new watchers on ST. Haha with better data then Dupixent This will be next SOC In acute and chronic asthma. Right now under the radar.

0 · Reply

StockScanners Nov. 21 at 4:57 AM

$CNTB reached 3.15

0 · Reply

SadyK189 Nov. 20 at 4:59 AM

Top Stocks to watch tomorrow 1 / 2: $SGBX $PACS $ZYXI $NUVB $CNTB SGBX: Initially alerted at 3.33. Kept posting about it regularly. Key support at 5.1 - 5.45. Next key level to test is 7.45 - 7.90. Currently at 6.60. PACS: Strong close of 4hours candle. Key support at 17.30 - 17.80. Next key level to test is 27.60 - 28.15. Currently at 24.50 CNTB is trending nicely on daily chart. Key support at 2.3 - 2.55. Next key level to test is 3.7 - 3.90. Currently at 3.20 NUVB: Good close of daily candle. 5.9 - 6.25 is acting as key support zone. Next key level to test is 7.85 - 8.25. Currently at 7.22 ZYXI: Overall trend is down but it can give good scalping opportunities of 15 - 20%. Currently at 0.6. Key support at 0.48 - 0.51. Next key level to test is 0.72 - 0.76

0 · Reply

StockScanners Nov. 20 at 2:36 AM

$CNTB reached 3.28

0 · Reply

Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 9:00 AM EST - 4 weeks ago

Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 3, 2025, 9:36 PM EST - 5 weeks ago

Connect Biopharma Holdings Limited (CNTB) Discusses Development Strategy for Next-Generation Biologic Targeting Acute and Chronic Respiratory Diseases Transcript

Sep 29, 2025, 9:00 AM EDT - 2 months ago

Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025

Sep 4, 2025, 8:00 AM EDT - 3 months ago

Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025

Sep 3, 2025, 8:00 AM EDT - 3 months ago

Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq

Aug 27, 2025, 9:00 AM EDT - 3 months ago

Connect Biopharma to Present at Two Upcoming Investor Conferences in September

Aug 14, 2025, 8:00 AM EDT - 4 months ago

Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide

Aug 13, 2025, 9:00 AM EDT - 4 months ago

Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 22, 2025, 9:00 AM EDT - 5 months ago

Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors

Jul 21, 2025, 9:00 AM EDT - 5 months ago

Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq

Jul 18, 2025, 9:00 AM EDT - 5 months ago

Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference

Jul 17, 2025, 9:00 AM EDT - 5 months ago

Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jun 13, 2025, 9:00 AM EDT - 6 months ago

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

Jun 3, 2025, 9:00 AM EDT - 6 months ago

Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

May 28, 2025, 9:00 AM EDT - 7 months ago

Connect Biopharma to Present at Two Upcoming Investor Conferences in June

May 20, 2025, 9:00 AM EDT - 7 months ago

Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference

May 15, 2025, 9:00 AM EDT - 7 months ago

Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 9:00 AM EDT - 7 months ago

Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD

May 13, 2025, 9:00 AM EDT - 7 months ago

Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

Apr 24, 2025, 9:00 AM EDT - 8 months ago

Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference

Apr 1, 2025, 9:00 AM EDT - 9 months ago

Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart

Mar 31, 2025, 4:05 PM EDT - 9 months ago

Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma

Mar 31, 2025, 9:00 AM EDT - 9 months ago

Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update

Mar 28, 2025, 4:05 PM EDT - 9 months ago

Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Mar 3, 2025, 8:00 AM EST - 10 months ago

Connect Biopharma to Present at Two Upcoming Investor Conferences

Oct 15, 2024, 7:30 AM EDT - 1 year ago

Attovia Therapeutics Appoints Chief Financial Officer

Oct 9, 2024, 3:55 PM EDT - 1 year ago

CNTB Stock Dips Amid Biotech Sector Volatility

Oct 2, 2024, 4:14 PM EDT - 1 year ago

CNTB Stock Surges Over 5% Amid Strong Financial Performance

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

Jul 1, 2024, 8:00 AM EDT - 1 year ago

Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum

Jun 12, 2024, 6:03 PM EDT - 1 year ago

Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jun 12, 2024, 4:15 PM EDT - 1 year ago

Connect Biopharma Announces New Leadership and Chair of the Board of Directors

May 22, 2024, 4:05 PM EDT - 1 year ago

Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma

May 7, 2024, 6:30 AM EDT - 1 year ago

Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma

Apr 16, 2024, 4:05 PM EDT - 1 year ago

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

Mar 19, 2024, 8:30 AM EDT - 1 year ago

Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference

Feb 12, 2024, 4:30 PM EST - 1 year ago

Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors

Dec 12, 2023, 6:00 AM EST - 2 years ago

Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

Dec 11, 2023, 4:05 PM EST - 2 years ago

Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

Nov 21, 2023, 6:03 AM EST - 2 years ago

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

Nov 21, 2023, 6:00 AM EST - 2 years ago

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

Nov 20, 2023, 4:41 PM EST - 2 years ago

Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023

Sep 12, 2023, 4:15 PM EDT - 2 years ago

Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update

Sep 12, 2023, 6:00 AM EDT - 2 years ago

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Aug 24, 2023, 6:21 PM EDT - 2 years ago

Connect Biopharma to Participate in Upcoming September Investor Conferences

Jul 10, 2023, 8:00 AM EDT - 2 years ago

Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology

Jul 5, 2023, 4:05 PM EDT - 2 years ago

Connect Biopharma to Participate in the SVB Securities Therapeutics Forum

Jun 1, 2023, 4:05 PM EDT - 2 years ago

Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis

Apr 11, 2023, 4:05 PM EDT - 2 years ago

Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update

RunnerSignals Dec. 2 at 8:20 PM

$BLTE $CDRE $CEVA $CHYM $CNTB Some serious fireworks here also! https://stocksrunner.com/news/2025-12-02-stock-upgrades-today-highlight-top-picks

0 · Reply

mikeywo Dec. 2 at 5:33 PM

$CNTB lackluster fireside chat ?

0 · Reply

DARKP00L Dec. 1 at 5:18 PM

$CNTB 12:01 on Dec. 01 2025 Lake Street Initiates Coverage On Connect Biopharma Hldgs with Buy Rating, Announces Price Target of $9 #tradeideas

0 · Reply

JarvisFlow Dec. 1 at 5:01 PM

Lake Street has updated their rating for Connect Biopharma Hldgs ( $CNTB ) to Buy with a price target of 9.

0 · Reply

LabPsycho Nov. 26 at 7:28 PM

$CNTB @mikeywo But can you trust the data?

2 · Reply

Schlombo Nov. 24 at 9:28 PM

$CNTB any thoughts on the 2 million shares picked up at close? Smart money? Maybe a rebalancing?

0 · Reply

mikeywo Nov. 21 at 12:42 PM

$CNTB picked up 16 new watchers on ST. Haha with better data then Dupixent This will be next SOC In acute and chronic asthma. Right now under the radar.

0 · Reply

StockScanners Nov. 21 at 4:57 AM

$CNTB reached 3.15

0 · Reply

SadyK189 Nov. 20 at 4:59 AM

0 · Reply

StockScanners Nov. 20 at 2:36 AM

$CNTB reached 3.28

0 · Reply

StockScanners Nov. 20 at 2:13 AM

$CNTB keep watch if this holds above 2.60

0 · Reply

nopainallgains Nov. 19 at 11:51 PM

$CNTB not many are talking about this one here. And I’d like to keep it that way until I’m finished loading 🤙🏻

0 · Reply

SmartMoneyTradez Nov. 19 at 11:32 PM

$CNTB Pumped before close and ah. Secured profits, left a moon bag

1 · Reply

ed53 Nov. 19 at 10:48 PM

$CNTB time to raise

0 · Reply

TheWings977 Nov. 19 at 9:21 PM

$CNTB go to $50 lol

0 · Reply

StockHunter75 Nov. 19 at 9:06 PM

$CNTB Going to rip higher.

0 · Reply

nopainallgains Nov. 19 at 8:59 PM

$CNTB 👀

0 · Reply

mikeywo Nov. 19 at 8:58 PM

$CNTB don’t do it Barry.

0 · Reply

_www_larval_com_ Nov. 19 at 8:57 PM

$CNTB 13%[23%] $DGNX -5%[-20%] $EPSM -3%[-17%] $GNPX -3%[-11%] $CYPH -3%[3%] most notable movement into the final minutes of trading.

0 · Reply

SmartMoneyTradez Nov. 19 at 7:20 PM

$CNTB Holding for one more day or till Friday morning

0 · Reply

SmartMoneyTradez Nov. 19 at 7:19 PM

$CCHH Paid well today $CNTB slow grind up

0 · Reply

StockScanners Nov. 19 at 3:55 AM

$CNTB reached 2.60

0 · Reply

Market Cap	131.37M
Revenue (ttm)	26.03M
Net Income (ttm)	-15.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-60.05%
Debt to Equity Ratio	0.00

Volume	104,100
Avg Vol	315,164
Day's Range	N/A - N/A
Shares Out	55.90M
Stochastic %K	27%
Beta	-0.19
Analysts	Strong Sell
Price Target	$7.90